Ketamine Archives - Spark Newswire

3 minute read

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch

May 18, 10:19 AM

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

ABBV

2 minute read

‘Not Even Trace Quantities:’ Tesla CEO Elon Musk Hits Back At Report Of Drug Use Allegations Worrying His Execs

By Benzinga Neuro

January 7, 9:27 PM

The Wall Street Journal report raised concerns about Musk's alleged drug use, prompting unease among his associates.

TSLA

2 minute read

Treating PTSD Topically & Directly To The Brain? Psychedelics Delivery Company Poised For Major Breakthrough

By Maureen Meehan

September 3, 2:45 PM

Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs directly to the brain, avoiding the traditional “high” and side effects.

BWVI

2 minute read

A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use

By Lara Goldstein

July 21, 3:12 PM

A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance.

CYBN

1 minute read

Parkinson’s Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track

By Nicolas Jose Rodriguez

May 3, 7:08 AM

Specialty pharmaceutical company PharmaTher Holdings (OTCQB: PHRRF) has submitted a Fast Track Application to the Food and D

PHRRF

1 minute read

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation

By Lara Goldstein

February 7, 4:36 PM

Specialty ketamine company PharmaTher Holdings Ltd.

PHRRF

2 minute read

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News

By Lara Goldstein

January 21, 3:52 PM

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

MSSTF

2 minute read

Exclusive: New Latin American JV To Provide More Psychedelic Medical Treatments For Mental Health Conditions

By Jelena Martinovic

November 22, 9:04 AM

Bienstar Wellness Brasil Ltda., a subsidiary of Bienstar Wellness Corp., has entered into a joint venture agreement with Dr. Sun Clinic, a Brazil-based clinic with more than 30 years of experience and more than 30.000 patients treated, specializing in multidisciplinary medical specialties.

NUMIF

2 minute read

Mental Health Provider Expands Psychedelic-Assisted Therapy For Chronic & Serious Medical Illnesses

By Lara Goldstein

October 28, 2:28 PM

Numinus Wellness Inc. (OTCQX: NUMIF) announced the launch of its new clinical program, ketamine for chronic and serious medical illness, to be first introduced at Utah, BC and Quebec clinics and then expanded to Numinus' remaining facilities.

NUMIF

2 minute read

Atai’s Phase 2 Study For Treatment-Resistant Depression Completes Enrollment, Expects Results Soon

By Lara Goldstein

October 26, 5:54 PM

Clinical stage psychedelics company atai Life Sciences (NASDAQ: ATAI) and its majority-owned subsidiary Perception Neuroscience completed patient enrollment for their Phase 2a clinical trial assessing the safety and efficacy of a single intravenous infusion (IV) dose of proprietary R-ketamine PCN-101 for patients

ATAI

Feed Tag: Ketamine